Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Mehta-Shah, N., Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Berta, S. K., Clemens, M. W., Dogan, A., Fisher, K., Goodman, A. M., Goyal, G., Guitart, J., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Lunning, M. A., Mehta, A., Olsen, E. A., Pro, B., Rajguru, S. A., Shanbhag, S., Shaver, A., Shustov, A., Sokol, L., Torka, P., Torres-Cabala, C., Wilcox, R., William, B. M., Zain, J., Dwyer, M. A., Sundar, H., Kim, Y. H. 2020; 18 (5): 523–36


Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

View details for DOI 10.6004/jnccn.2020.0022

View details for Web of Science ID 000531161900007

View details for PubMedID 32380458